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As one of the primary mechanisms by which dopamine signaling is regulated, the dopamine 
transporter (DAT) is an attractive pharmacological target for the treatment of diseases 
based in dopaminergic dysfunction. In this work we demonstrate for the first time that the 
commonly prescribed breast cancer therapeutic tamoxifen and its major metabolites,  4-
hydroxytamoxifen and endoxifen, inhibit DAT function. Tamoxifen inhibits [3
 
H]dopamine 
uptake into hDAT-N2A cells via an uncompetitive or mixed mechanism. Endoxifen, an 
active metabolite of tamoxifen, asymmetrically inhibits DAT function in hDAT-N2A cells, 
showing a preference for the inhibition of amphetamine-stimulated dopamine efflux as 
compared to dopamine uptake. Importantly, we demonstrate that the effects of tamoxifen 
and its metabolites on the DAT occur independently of its activity as selective estrogen 
receptor modulators. This work suggests that tamoxifen is inhibiting DAT function through 
a previously unidentified mechanism.  
List of abbreviations:  
DAT, dopamine transporter; hDAT, human dopamine transporter; DA, dopamine; SERM, 
selective estrogen receptor modulator; PKC, protein kinase C; TMX, tamoxifen; endox, 
endoxifen; 4OH, 4-hydroxytamoxifen; ER, estrogen receptor; GPER1, G-protein coupled 
estrogen receptor 1; KRH, Krebs Ringer Hepes buffer; S.E.M., standard error of the mean. 
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The dopamine transporter (DAT) is a key mechanism by which extracellular dopamine is 
removed from the extracellular space following its release from neurons, and as such plays 
a vital role in the regulation of dopamine signaling.  Pharmacological modulation of the 
DAT, therefore, is a source of great interest for the treatment of multiple dopaminergic 
diseases.  
The breast cancer therapeutic tamoxifen is a well-established pharmaceutical agent 
with a clear safety profile; however, tamoxifen has multiple actions beyond its original 
designation as a selective estrogen receptor modulator (SERM). Various studies have 
demonstrated that tamoxifen can modulate the dopaminergic system. For example, 
tamoxifen inhibits amphetamine-stimulated hyperactivity in rodents, potentially through 
inhibition of protein kinase C (Einat et al. 2007). Tamoxifen also has efficacy as a 
neuroprotectant in models of dopaminergic neurotoxicity (Bourque et al. 2007, Obata & 
Kubota 2001). However, the mechanism by which tamoxifen affects the dopaminergic 
system remains incompletely elucidated. 
Estrogen is well known to affect DAT function; it stimulates dopamine efflux and 
enhances amphetamine-stimulated dopamine efflux (Xiao et al. 2003, Becker 1990). There 
are three known estrogen receptors: ERα, ERβ, and the G-protein coupled estrogen 
receptor (GPER1). All three receptors modulate DAT function to varying degrees (Alyea & 
Watson 2009, Alyea et al. 2008). Beyond its SERM activity at ERα and ERβ, tamoxifen is 
also an agonist at GPER1 (Thomas et al. 2005).  
Tamoxifen is metabolized into three active metabolites that reach appreciable levels 
in the brain: 4-hydroxytamoxifen, N-desmethyltamoxifen, and 4-hydroxy-N-
desmethyltamoxifen (known as endoxifen). 4-Hydroxytamoxifen and endoxifen are 
considered the active metabolites of tamoxifen, because their potency as SERMs is 100-fold 
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higher than the parent compound (Lien et al. 1991). Any combination of these metabolites 
could be responsible for the effects of tamoxifen on the dopaminergic system.  
 In this study we hypothesized that tamoxifen would inhibit function of the 
dopamine transporter.  We demonstrate for the first time that tamoxifen inhibits DAT 
function through an uncompetitive or mixed mechanism. We also determine that two of 
tamoxifen’s active metabolites, 4-hydroxytamoxifen and endoxifen also inhibit transporter 
function. Through blockade of the estrogen receptors with selective antagonists, we 
confirm that tamoxifen and its metabolites inhibit DAT function independently of their 
actions at any of the estrogen receptors. 
 
Materials 
All chemicals were obtained from Sigma Aldrich with the exception of [3
Cell culture 
H]dopamine, which 
was purchased from Perkin Elmer, and G36, which was purchased from Tocris. Tamoxifen 
citrate, endoxifen, 4-hydroxytamoxifen, and G36 were prepared as a 50 mM stock and 
fulvestrant as a 10 mM stock in dimethylsulfoxide (DMSO). Stock solutions were diluted in 
the buffers appropriate for the assay.  Final concentration of DMSO in all solutions ranged 
from 0.01-0.03% and were kept constant across all conditions within an experiment.  
N2 mouse neuroblastoma cells stably expressing the human DAT (hDAT-N2a) cells were 
grown in Optimem reduced serum media (Gibco) supplemented with fetal bovine serum 
(10%), penicillin-strepavidin (1%), and G418 (100 µg/ml, Gibco) at 37 °C in 5% CO2. For 
experiments involving estrogen receptor antagonists, cells were maintained under the 
same conditions and in a similar media formulation except that the Optimem was free of 
phenol-red and was supplemented with a charcoal-stripped bovine serum (kindly provided 
by Dr. James Rae, University of Michigan) in order to limit exposure of the cells to 
exogenous estrogens. For assays measuring dopamine uptake and amphetamine-
stimulated dopamine efflux, cells were trypsinized 1-2 days before the experiment and 
seeded on 24-well plates (50,000 to 100,000 cells per well); at the time of the experiment, 
cell density approached confluency with approximately 200,000 cells per well. All 
experiments were carried out in triplicate and repeated with at least three different 
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cultures of the cells. All experiments were carried out in concordance with the safety 
guidelines of the University of Michigan. 
[3
Cells were grown in 24-well plates.  Media was aspirated from the wells and cells were 
washed three times with Krebs Ringer HEPES buffer (KRH, pH 7.4, 25 mM HEPES, 125 mM 
NaCl, 4.8 mM KCl, 1.2 mM KH
H]Dopamine uptake  
2PO4, 1.3 mM CaCl2, 1.2 mM MgSO4, 5.6 mM glucose, 50 μM 
pargyline, and 50 μM ascorbic acid) before the addition of 400 μl of drug or vehicle in KRH. 
Vehicle or drugs were present throughout the experiment. All experiments were conducted 
at room temperature. After a one-hour incubation with vehicle or drugs, 100 µM cocaine 
was added to non-specific wells, and [3H]dopamine uptake was initiated 10 minutes later. 
For the concentration response curves, [3H]dopamine uptake was initiated by the addition 
of 10 nM [3H]dopamine supplemented with 300 nM unlabeled dopamine and the reaction 
was terminated after 10 minutes. In assays measuring uptake kinetics, dopamine uptake 
was initiated by 10 nM [3H]dopamine supplemented with 10 nM to 3 μM unlabeled 
dopamine and the reaction was terminated after 5 minutes. [3
[
H]Dopamine uptake was 
terminated by aspiration of the solution followed by three rapid washes with ice cold KRH. 
Cells in each well were lysed with 400 μl of 2 M perchloric acid and transferred to 
scintillation vials with 5 mls of Scintiverse Scintillation Cocktail (Fisher Scientific) and 
counted on a Beckman scintillation counter.  
3
Media was aspirated from wells and cells were washed three times with KRH before the 
addition of 200 μl of 50 nM [
H]Dopamine efflux 
3H]dopamine plus 5 μM unlabeled dopamine in KRH and 
incubation at room temperature. After 40 minutes of [3H]dopamine loading, each well was 
rapidly washed with KRH three times. KRH plus drugs or vehicle were added to each well. 
A stable baseline was established by removing and replacing the extracellular solution 
every 10 minutes for a total of 50 minutes. Beginning at 50 minutes, three 10 minute 
fractions were collected with 20 µM amphetamine added during the second fraction. 
Baseline was defined as the counts per minute in the fraction immediately preceding the 
addition of amphetamine.  Following removal of the final fraction, cells were lysed with 2 M 
perchloric acid to quantify total remaining dopamine content. Experiments were carried 
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out in triplicate.  An additional well was reserved for each treatment condition which 
received no amphetamine in order to quantify non-specific dopamine release. Dopamine 
efflux was quantified as the percentage of the [3H]dopamine content released during the 
efflux fraction divided by the total [3
Measurement of surface DAT by biotinylation 
H]dopamine present in the cells.  
hDAT-N2A cells were incubated with 3 µM tamoxifen in KRH for 1 hr. The amount of cell 
surface DAT was determined in these cells with biotinylation using previously described 
method (Guptaroy et al. 2009) with minor modifications. Avidin beads (80 µl) were used to 
pull down biotinylated cell surface proteins from cells lysates (400 µg). Total and 
biotinylated fraction of DAT was measured by SDS-PAGE and immunoblotting using anti-
DAT antibody. 
Statistical analysis 
Statistical analyses were carried out using Graphpad Prism 6 (San Diego, CA). Data are 
plotted as mean ± the standard error of the mean (S.E.M.).  Significance was set at p<0.05. 
Comparisons between multiple groups were made with one-way analysis of variants 
(ANOVA), with post hoc Dunnett’s multiple comparison test. Non-linear regression was 
used to determine IC50, Vmax, and Km values. Calculated Km and Vmax
 
 values were compared 
across experiments by a one-way ANOVA. Kinetic data for tamoxifen were also analyzed 
using Line-weaver Burke analysis in Prism 6. When concentration response curves were 
compared, comparison of fits in non-linear regression was used to determine whether 
curves differed from each other. The null hypothesis was that the best fit parameter for the 
value did not differ.   
Tamoxifen and the active metabolites 4-hydroxytamoxifen and endoxifen inhibit 
amphetamine-stimulated dopamine efflux and dopamine uptake in hDAT-N2A cells. In 
order to characterize the effects of tamoxifen on DAT function, we quantified [3H]dopamine 
uptake and amphetamine-stimulated [3H]dopamine efflux in hDAT-N2A cells following 1-
hour pretreatment with the increasing concentrations of tamoxifen (Figure 1A). One-way 
repeated measures ANOVA indicated a significant effect of tamoxifen treatment on 
[3H]dopamine uptake (F(5, 20) = 32.74, p<0.0001) and efflux (F(5, 20) = 41.28, p<0.0001) 
compared to vehicle. Post hoc Dunnett’s multiple comparisons test revealed a significant 
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decrease in dopamine uptake for 3 μM (p<0.001) and 10 μM (p<0.0001) tamoxifen and a 
significant decrease in dopamine efflux for 0., 1 μM (p<0.001), 3 μM (p<0.01), and 10 μM 
(p<0.0001) tamoxifen compared to vehicle. There was no significant difference between 
the concentration response curves generated for dopamine uptake and amphetamine-
stimulated dopamine efflux in hDAT-N2A cells (Figure 1A). See Table 1 for IC50
 
 values.  
The effects of the active metabolites of tamoxifen on the DAT were characterized. N-
desmethyltamoxifen had no effect on [3
 In hDAT-N2A cells, a repeated measures one-way ANOVA indicated a significant 
effect of 4-hydroxytamoxifen treatment on [
H]dopamine uptake or efflux through the DAT at 
concentrations up to 3 μM, but was cytotoxic at higher concentrations as measured by 
PrestoBlue (ThermoFisher, data not shown). Tamoxifen and the two remaining 
metabolites, 4-hydroxytamoxifen and endoxifen were not toxic at any of the concentrations 
tested; therefore our focus was on these three compounds. 
3H]dopamine uptake (F(5, 15) = 33.68, 
p<0.0001) and efflux (F(5, 10) = 31.63, p<0.0001) (Figure 1B). Post hoc Dunnett’s multiple 
comparisons test revealed a significant decrease in [3H]dopamine uptake for 1 μM 
(p<0.05), 3 μM (p<0.0001) and 10 μM (0.0001) 4-hydroxytamoxifen and a significant 
decrease in amphetamine-stimulated [3
A one-way repeated measures ANOVA indicated a significant effect of endoxifen 
treatment on [
H]dopamine efflux for 3 μM (p<0.001), and 10 μM 
(p<0.0001) 4-hydroxytamoxifen compared to vehicle. The concentration response curves 
generated by these two data sets were not significantly different from each other.  
3H]dopamine uptake (F(4, 12) = 8.24, p<0.01) and amphetamine-stimulated 
[3H]dopamine efflux (F(4, 12) = 53.63, p<0.0001) (Figure 1C). Post hoc Dunnett’s multiple 
comparisons test revealed a significant decrease  in [3H]dopamine uptake at 3 μM (p<0.01) 
endoxifen and a significant decrease in amphetamine-stimulated [3H]dopamine efflux at 1 μM (p<0.001) and 3 μM (p<0.0001) endoxifen as compared to vehicle. The concentration 
response curves generated by these two data sets were significantly different from each 
other (F(1,30) =20.78, (p<0.0001)) with endoxifen exhibiting increased potency for the 
inhibition of [3
Tamoxifen effect on dopamine uptake kinetics 
H]dopamine efflux compared to uptake (Table 1).  
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To further investigate the action of tamoxifen at the DAT, we determined the effects of 
tamoxifen on [3H]dopamine uptake kinetics in hDAT-N2A cells. Tamoxifen significantly 
decreased the Vmax of dopamine uptake at 3 μM and 10 μM. At 10 μM, tamoxifen also 
significantly decreased the Km of [3H]dopamine uptake (Figure 2A, Table 2).  At 3 µM, 
tamoxifen significantly decreases the Vmax of dopamine uptake without having a significant 
effect on Km.  Lineweaver-Burke analysis (inset, Fig.2) indicates that the inhibition by 3 µM 
tamoxifen is uncompetitive, because Vmax/Km for individual vehicle vs 3 µM tamoxifen did 
not change (0.05 ± 0.004 vs 0.045 ± 0.005 S.E.M., respectively).  Analysis of inhibition by 10 
µM tamoxifen showed mixed inhibition (Vmax/Km = 0.024 ± 0.007, p < 0.02 vs vehicle). The 
reduction in [3
Effect of estrogen antagonists 
H]dopamine uptake was not due to a reduction in surface DAT (Figure 2B).  
Incubation of hDAT-N2A cells with 3 µM tamoxifen for one hour had no effect on surface 
levels of the DAT (2-tailed t-test, t=1.020 df=8, p = 0.337).   
N2A mouse neuroblastoma cells express all three known estrogen receptors (Su et 
al. 2012, Mendez & Garcia-Segura 2006, Manthey et al. 2010). Because tamoxifen and its 
metabolites are SERMS, we sought to determine whether their actions on the DAT might be 
attributable to their activity at any of the three estrogen receptors. The hDAT-N2A cells 
used in these experiments were maintained in medium supplemented with charcoal 
stripped fetal bovine serum in order to preclude complications that might arise from the 
presence of exogenous estrogens. Using the ERα and ERβ antagonist fulvestrant (3 μM), 
and the GPER1 antagonist G36 (10 μM), we found that blockade of the estrogen receptors 
had no significant effect on basal [3H]dopamine uptake or amphetamine-stimulated 
[3H]dopamine efflux. Moreover, neither fulvestrant nor G36 inhibited the effects of 
tamoxifen or its metabolites on [3H]dopamine uptake or amphetamine-stimulated 
[3
 
H]dopamine efflux (Figure 3). 
 In this study we demonstrate that tamoxifen and two of its active metabolites, 4-
hydroxytamoxifen and endoxifen, impair DAT function independently of their actions at the 
estrogen receptors. We also demonstrate that in cells, tamoxifen impairs dopamine uptake 
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through a mixed mechanism.   This suggests that tamoxifen has a preference for binding to 
the substrate-occupied transporter indicating an allosteric mechanism of action.  
 In our investigation of the effects of tamoxifen and its metabolites on the DAT, it was 
necessary that we consider the potential effects of the drugs’ SERM activity on DAT 
function. We found that antagonists of the estrogen receptors had no effect on 
amphetamine-stimulated dopamine efflux or dopamine uptake on their own, and did not 
alter the ability of tamoxifen or its metabolites to inhibit forward or reverse transport. By 
failing to antagonize the effects of tamoxifen and its metabolites on the DAT, these 
experiments demonstrated that tamoxifen is not exerting its effects on the DAT through an 
estrogenic mechanism. Furthermore, because the antagonists themselves had no effect on 
dopamine uptake or efflux, an antiestrogenic effect of tamoxifen or its metabolites is 
insufficient to explain its inhibition of DAT function. These conclusions are further 
supported by previous observations that fulvestrant but not tamoxifen is capable of 
antagonizing the effect of estrogen on amphetamine-stimulated efflux (Xiao et al. 2003). 
Additionally, endoxifen and 4-hydroxytamoxifen are 100-fold more potent in their actions 
at the estrogen receptors, relative to tamoxifen (Lien et al. 1991), but all of the compounds 
tested display IC50
Though tamoxifen and 4-hydroxytamoxifen exhibit similar effects on uptake and efflux our 
results indicate that endoxifen preferentially inhibits dopamine efflux in the cells.  The 
difference between the effects of endoxifen on dopamine uptake and amphetamine-
stimulated dopamine efflux in the cells is intriguing. In the cell-based assay in which 
[
s in the micromolar range for reduction of DAT function.  The diphenyl 
structural motif in tamoxifen and its metabolites could partially account for their blockade 
of dopamine uptake; this motif also exists in DAT blockers such as modafinil and 
benztropine (Schmitt et al. 2013). 
3H]dopamine is exogenously loaded, the [3H]dopamine efflux measured is actually the 
difference between the outward transport of dopamine and the amount of dopamine taken 
back up in to the cell during assay. Thus an inhibitor of dopamine uptake might be expected 
to display less of an effect on amphetamine-stimulated dopamine efflux, because the 
blockade of reuptake might obfuscate a reduction in efflux. This was not true of endoxifen, 
however.  Another activity of endoxifen might play a role in the enhanced potency for 
reverse transport.  Tamoxifen and its metabolites, including endoxifen, inhibit protein 
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kinase C activity  (O'Brian et al. 1985). In cell-based assays, tamoxifen exhibits micromolar 
potency in the inhibition of PMA-stimulated phosphorylation of PKC substrates 
(unpublished data). Our previous studies (Johnson et al. 2005, Kantor & Gnegy 1998) have 
shown that protein kinase C inhibitors reduce amphetamine-stimulated dopamine efflux 
but do not inhibit dopamine reuptake. Thus, at the concentrations tested here, it is 
reasonable to expect that tamoxifen and its metabolites are inhibiting PKC, although this 
may not contribute to the reduction in dopamine uptake.  It is possible that the enhanced 
effectiveness of endoxifen in reducing dopamine efflux is due to a PKC-dependent 
inhibition of amphetamine-stimulated dopamine efflux, however.  Reportedly, endoxifen is 
more potent at inhibiting PKC than is tamoxifen (Ali et al. 2010). 
 This work demonstrates for the first time that tamoxifen inhibits function of the 
DAT independently of its actions as a selective estrogen receptor modulator. Future work 
will aim to better characterize the interaction between the DAT and tamoxifen and clarify a 
mechanism of action for these observations. 
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Fig 1. 3 - 3
-  following a 1-hour treatment with (A) tamoxifen (TMX, n=5), (B) 4-
hydroxytamoxifen (4OH, n=3-4), and (C) endoxifen (Endox, n=4). Comparison of fits for 
non-linear regression indicated no difference between the concentration response curves 
for uptake vs. efflux for tamoxifen or 4-hydroxytamoxifen but a significant difference 
between the concentration response curves for uptake vs. efflux for endoxifen. *efflux, 
p<0.05 vs vehicle; **efflux, p<0.01 vs vehicle; ***efflux, p<0.001 vs vehicle; ****efflux, 
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p<0.0001 vs vehicle; • uptake, p<0.05; •• uptake, p<0.01; ••• uptake, p<0.001; •••• uptake, 
p<0.0001.  
 
 [3 - , 
  4-H   
 4.4 μM (3.0 to 6.3) 3.6 μM (2.5 to 5.0) 6.7 μM (3.7 to 12) *** 
 4.5 μM (2.7 to 7.4) 2.6 μM (1.8 to 3.7) 1.3 μM (0.9 to 1.9) 
 (95% CI)  ***p<.001 vs. IC50
 
 for efflux 
- [3
-  
 
(n=6) μ (n=3) μ (n=3) 
V 34.5 ± 2.8  (  13.8 ± 2.1** 4.9 ± 0.9**** 
Km 430.9 ± 57.2  (  232.6 ± 33.7 148.6 ± 53.9* 
*p<0.05, **p<0.01, ****p<0.0001 vs. vehicle, One-way ANOVA with Dunnett’s post hoc 
multiple comparisons. 
 
3 3
-   hDAT-N2A cells were 
treated with vehicle, 3 μM, or 10 μM tamoxifen (TMX). [3H]DA uptake was measured for 5 
min as described in Methods. Comparison of fits indicated a significant effect of both 
concentrations of tamoxifen on Vmax but not Km
 
 compared to vehicle (p<0.0001). (A, inset) 
Lineweaver-Burke plot of the data. Data are represented as mean ± S.E.M.. B. Surface DAT 
was measured by biotinylation following a 1 hr incubation with vehicle or 3 as described in 
Methods.  N=5.  
3 3
- 3 . Inhibition of [3H]dopamine uptake (A, C, E) 
and amphetamine-stimulated [3H]dopamine efflux (20 μM amphetamine, B, D, F) by 
tamoxifen (10 μM, A, B), 4-hydroxytamoxifen (3 μM, C, D), and endoxifen (3 μM, E, F) were 
measured in the presence and absence of the ERα/ERβ antagonist fulvestrant (3 μM) or the 
GPER1 antagonist G36 (10 μM). The presence of the estrogen receptor antagonists had no 
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significant impact on amphetamine-stimulated [3H]dopamine efflux or [3
 
H]dopamine 
uptake and failed to affect the ability of tamoxifen and its metabolites to inhibit these 
activities. N=3 
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